DE69918690D1 - Stabile igf/igfbp pharmazeutische formulierungen - Google Patents

Stabile igf/igfbp pharmazeutische formulierungen

Info

Publication number
DE69918690D1
DE69918690D1 DE69918690T DE69918690T DE69918690D1 DE 69918690 D1 DE69918690 D1 DE 69918690D1 DE 69918690 T DE69918690 T DE 69918690T DE 69918690 T DE69918690 T DE 69918690T DE 69918690 D1 DE69918690 D1 DE 69918690D1
Authority
DE
Germany
Prior art keywords
igfbp
igf
pharmaceutical formulations
complex
stable igf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69918690T
Other languages
English (en)
Other versions
DE69918690T2 (de
Inventor
Stephen Danko
David Passmore
Yasushi Ogawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Publication of DE69918690D1 publication Critical patent/DE69918690D1/de
Application granted granted Critical
Publication of DE69918690T2 publication Critical patent/DE69918690T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69918690T 1998-06-01 1999-05-28 Stabile igf/igfbp pharmazeutische formulierungen Expired - Lifetime DE69918690T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89062 1998-06-01
US09/089,062 US6436897B2 (en) 1998-06-01 1998-06-01 Pharmaceutical formulations for IGF/IGFBP
PCT/US1999/012173 WO1999062536A2 (en) 1998-06-01 1999-05-28 Pharmaceutical formulations for igf/igfbp

Publications (2)

Publication Number Publication Date
DE69918690D1 true DE69918690D1 (de) 2004-08-19
DE69918690T2 DE69918690T2 (de) 2005-08-18

Family

ID=22215473

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918690T Expired - Lifetime DE69918690T2 (de) 1998-06-01 1999-05-28 Stabile igf/igfbp pharmazeutische formulierungen

Country Status (14)

Country Link
US (2) US6436897B2 (de)
EP (1) EP1082133B1 (de)
JP (1) JP2002516871A (de)
KR (1) KR20010052500A (de)
CN (1) CN1201816C (de)
AT (1) ATE270898T1 (de)
AU (1) AU4326799A (de)
BR (1) BR9910863A (de)
CA (1) CA2330925C (de)
DE (1) DE69918690T2 (de)
ES (1) ES2221456T3 (de)
HK (1) HK1040637B (de)
IL (1) IL139969A0 (de)
WO (1) WO1999062536A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
ES2180416B1 (es) * 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
US20100143442A1 (en) 2003-02-05 2010-06-10 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
AU2003900481A0 (en) 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
AU2003903896A0 (en) 2003-07-28 2003-08-07 Queensland University Of Technology Skin regeneration system
ES2395035T3 (es) 2004-08-17 2013-02-07 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de la IL-1
EP1674113A1 (de) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol)
ES2341270T3 (es) * 2004-12-24 2010-06-17 Insmed, Inc. Complejos rhigf-i/rhigfbp-3 purificados y procedimientos de fabricacion de los mismos.
WO2006087643A2 (en) * 2005-01-25 2006-08-24 Wyeth Research Ireland Limited Method for diafiltration
PT1861116E (pt) 2005-03-25 2015-11-04 Regeneron Pharma Formulações de antagonista do vegf
EP1909831A4 (de) 2005-06-14 2013-02-20 Amgen Inc Selbstpuffernde proteinformulierungen
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
EP2059530B1 (de) 2006-08-31 2012-08-29 F.Hoffmann-La Roche Ag Verfahren zur herstellung des insulinähnlichen wachstumsfaktors-i
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
KR101383476B1 (ko) 2007-11-01 2014-04-11 아스테라스 세이야쿠 가부시키가이샤 면역억제 폴리펩티드 및 핵산
EP2352514A4 (de) 2008-10-29 2012-07-25 Univ Rockefeller Verfahren und kits zur krankheitsbehandlung durch verabreichung des einen insulinähnlichen wachstumsfaktor bindenden proteins 2
RU2012127364A (ru) 2009-11-30 2014-01-10 Квинсленд Юниверсити Оф Текнолоджи Химеры фибронектин: фактор роста
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US20190293527A1 (en) * 2013-02-04 2019-09-26 Charm Sciences, Inc. Extraction of mycotoxins
US11035764B2 (en) * 2012-02-03 2021-06-15 Charm Sciences, Inc. Extraction of mycotoxins
BR112015004984A2 (pt) 2012-09-07 2017-07-04 Coherus Biosciences Inc formulações aquosas estáveis de adalimumab
EP3170005B1 (de) 2014-07-18 2019-04-10 Sanofi Verfahren zur vorhersage des ausgangs einer behandlung mit aflibercept bei einem patienten mit verdacht auf ein krebsleiden
US20180188139A1 (en) * 2015-06-22 2018-07-05 Dots Technology Corp. Improved assays and methods for allergen detection
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
ES2956007T3 (es) 2015-12-03 2023-12-11 Regeneron Pharma Métodos de asociación de variantes genéticas con un resultado clínico en pacientes que padecen degeneración macular asociada a la edad tratados con anti-VEGF
EP3397644A4 (de) * 2015-12-31 2018-12-19 Siemens Healthcare Diagnostics Inc. Nicht-rekombinantes humanes insulin-like-wachstumsfaktorbindendes proteinkonzentrat
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
JP2019534263A (ja) 2016-10-07 2019-11-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 室温で安定な凍結乾燥タンパク質
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
IL301688A (en) * 2020-10-19 2023-05-01 Oak Hill Bio Ltd The compositions are suitable for use in newborns
WO2023139250A1 (en) * 2022-01-24 2023-07-27 Oak Hill Bio Limited Lot release assays for igf‐1/igfbp complexes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
WO1995008567A1 (en) 1993-09-20 1995-03-30 Celtrix Pharmaceuticals, Inc. Treatment of immunologic and hematologic disorders with igfbp alone or complexed with igf
CA2176708A1 (en) 1993-11-15 1995-05-26 Christopher A. Maack Method of treating neurological disorders
CA2176709A1 (en) * 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
US5861273A (en) 1993-12-21 1999-01-19 Celtrix Phamraceuticals, Inc. Chromosomal expression of heterologous genes in bacterial cells
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
US5948757A (en) * 1996-03-01 1999-09-07 Celtrix Pharmaceuticals, Inc. High dose IGF-1 therapy
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition

Also Published As

Publication number Publication date
ES2221456T3 (es) 2004-12-16
CA2330925A1 (en) 1999-12-09
EP1082133B1 (de) 2004-07-14
HK1040637B (zh) 2006-01-06
JP2002516871A (ja) 2002-06-11
US20030087806A1 (en) 2003-05-08
US6436897B2 (en) 2002-08-20
CA2330925C (en) 2010-02-09
DE69918690T2 (de) 2005-08-18
EP1082133A2 (de) 2001-03-14
AU4326799A (en) 1999-12-20
WO1999062536A3 (en) 2000-03-30
CN1315868A (zh) 2001-10-03
WO1999062536A2 (en) 1999-12-09
US20020004478A1 (en) 2002-01-10
IL139969A0 (en) 2002-02-10
CN1201816C (zh) 2005-05-18
BR9910863A (pt) 2002-06-11
KR20010052500A (ko) 2001-06-25
HK1040637A1 (en) 2002-06-21
ATE270898T1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
DE69918690D1 (de) Stabile igf/igfbp pharmazeutische formulierungen
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
EE04452B1 (et) Farmatseutiliselt aktiivne morfolinool ja selle kasutamine
EP1100522A4 (de) Verabreichung aktiver wirkstoffe über die lunge
ATE345133T1 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
PT1058558E (pt) Vacinas vivas recombinantes administradas com adjuvante
DE69918074D1 (de) Makrolid-formulierung mit verzögerter wirkstoffabgabe
DE59900369D1 (de) Stickoxidemissionsmindernde Abgasreinigungsanlage
DK2130554T3 (da) Albuminfrie faktor VIII-præparater
EE04617B1 (et) 2,3-diarüülpürasolo[1,5-b]püridasiini derivaadid,nende valmistamine ja kasutamine tsüklooksügenaas2 (COX-2) inhibiitoritena
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
FI960750A0 (fi) Hermon kasvutekijän farmaseuttiset formulaatiot
KR950031103A (ko) 단백질 함유의 안정한 동결-건조 제제
HUP0100090A2 (hu) Szájápoló készítmények
BR0012429A (pt) Fórmulações para il-11
CY1108815T1 (el) Διαδοχικη χορηγηση cpt-11 και πολυπεπτιδιου apo-2l
PT1220693E (pt) Formulacoes para libertacao de proteinas osteogenicas
DE69827357D1 (de) Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung
SE9702680D0 (sv) New formulation
DK1014987T3 (da) Orale præparater med levosimendan
DE68903858D1 (de) Orale mittel fuer wiederkaeuer.
DK0759775T3 (da) Flydende IFN-beta-formuleringer
SE9402880D0 (sv) New peptide derivatives
SE9604795D0 (sv) New pharmaceutical formulation
ATE245028T1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition